Showing Results for
- Academic Journals (1,077)
Search Results
- 1,077
Academic Journals
- 1,077
-
From:Journal of Clinical Investigation (Vol. 124, Issue 6) Peer-ReviewedRecent attempts to develop an HIV-1 vaccine indicate that viral replication can be limited by the induction of viral-specific T cell responses; however, recent trials of vaccine candidates designed to target [CD8.sup.+]...
-
From:Clinical Advisor (Vol. 14, Issue 9)An elderly patient presented with an acute reaction of shingles. How soon after treatment is it advisable to administer the zoster vaccine (Zostavax)? A month? A year? I have got-ten conflicting answers from both sides...
-
From:Expert Review of Clinical Pharmacology (Vol. 2, Issue 6) Peer-ReviewedAuthor(s): Peter Kelleher 1 Most effective vaccines were produced before we had an extensive knowledge of the mechanisms involved in protection. Although the majority of successful vaccines produce neutralizing...
-
From:HIV Therapy (Vol. 4, Issue 1)Author(s): Tamara Bar-Magen 1 , Richard D Sloan 1 , Mark A Wainberg [[dagger]] 1 Restriction factors & replication A major theme was cellular factors that are responsible for regulating and restricting viral...
-
From:Expert Review of Vaccines (Vol. 9, Issue 9) Peer-ReviewedAuthor(s): Kazuhiro Matsuo [[dagger]] 1 , Naoki Yamamoto 2 Keywords : AIDS; cell-mediated immunity; HIV; humoral immunity; prime-boost regimen; recombinant BCG; vaccine Current status of HIV/AIDS vaccine...
-
From:Future Virology (Vol. 1, Issue 4)A global consortium of researchers, supported by the Center for HIV/AIDS Vaccine Immunology, aims to develop novel vaccines by examining the genetic differences in the immune response to HIV The Center for HIV/AIDS...
-
From:Future Virology (Vol. 1, Issue 6)Author(s): Margaret Wecker BAJFIJJC , Renee Ridzon BAJCCFHI , Susan M Graham BAJJEGEA , Ann Duerr [[dagger]] BAJGFBDH Keywords: circumcision; genital herpes; HIV; microbicides; pre-exposure prophylaxis;...
-
From:PharmaGenomics (Vol. 4, Issue 2) Peer-ReviewedIn other HIV treatment news, Chiron Corporation (Emeryville, CA, USA) announced the initiation of a clinical trial for its HIV vaccine candidate. The vaccine attempts to generate cellular immune response together with...
-
From:Expert Review of Vaccines (Vol. 2, Issue 6) Peer-ReviewedA preventive AIDS vaccine, HIVA.MVA, has begun clinical trials in Switzerland and South Africa. Trials of HIVA.MVA are already underway in Kenya, Uganda and the UK. Research centers involved include the Chris...
-
From:Expert Review of Anti-infective Therapy (Vol. 1, Issue 4) Peer-ReviewedA preventive AIDS vaccine, HIVA.MVA, has begun clinical trials in Switzerland and South Africa. Trials of HIVA.MVA are already underway in Kenya, Uganda and the UK. Research centers involved include the Chris...
-
From:Sister Namibia (Vol. 15, Issue 5-6) Peer-ReviewedThe participation by women in HIV/AIDS vaccine trials in Kenya and Uganda has been hampered by cultural inhibitions, scientists in the trials said recently. Trials of a vaccine that promises to provide a solution to HIV...
-
From:Science (Vol. 252, Issue 5005) Peer-ReviewedFrench AIDS researcher Daniel Zagury has come under sharp attack by a Paris hospital, the French and American press, and, most recently, the French Minister of Health, for his experiments involving a genetically...
-
From:Science (Vol. 250, Issue 4980) Peer-ReviewedOn the evening of Saturday, 11 August, sometime after 6:50 but before 11:00, an intruder reportedly broke into the unoccupied Bethesda home of AIDS researcher Robert C. Gallo. The break-in occurred while Gallo was at a...
-
From:Science (Vol. 258, Issue 5082) Peer-ReviewedBiotech firm MicroGeneSys launched a lobbying blitz to get its "therapeutic vaccine" tested. Has their success skewed the effort to develop vaccines as a form of AIDS therapy? One of the most intriguing ideas to come...
-
From:Science (Vol. 255, Issue 5042) Peer-ReviewedThe storm that has been swirling around AIDS vaccine researcher Daniel Zagury for more than a year may be beginning to clear. A French organization that licenses physicians and oversees medical ethics has rejected a...
-
From:Science (Vol. 260, Issue 5112) Peer-ReviewedResearchers have used both traditional methods and methods using genetic engineering to develop AIDS vaccines. Traditional methods use uses material from the actual HIV virus. Genetic engineering approaches enable...
-
From:Science (Vol. 270, Issue 5238) Peer-ReviewedMolecular biologist Nicholas Deacon and his team have discovered that a man infected with HIV in the early 1980s who has not developed AIDS or transmitted the virus was infected with a very weak HIV strain that lacks...
-
From:PLoS ONE (Vol. 9, Issue 1) Peer-ReviewedAuthor(s): Lyle R. McKinnon 1,2, Sean M. Hughes 3, Stephen C. De Rosa 6,12, Jeffrey A. Martinson 4, Jill Plants 4, Kirsten E. Brady 4, Pamela P. Gumbi 5, Devin J. Adams 6, Lucia Vojtech 3, Christine G. Galloway 6,...
-
From:Nature (Vol. 455, Issue 7213) Peer-ReviewedRecent advances in immunology and failures in HIV-vaccine development suggest that it is time to rethink the current approach to developing an HIV vaccine. Better communication and cooperation is needed between...
-
From:Expert Review of Vaccines (Vol. 5, Issue 4) Peer-ReviewedAuthor(s): Barton F Haynes [[dagger]] 1 , David C Montefiori 2 Keywords: antiretroviral therapy; HIV-1; host cell fusion; immunogen; neutralizing antibody induction Development of a safe, practical and...